As a member of the protein kinase C family, PRKCI affects tumorigenesis, progression and chemosensitivity by regulating the Wnt/beta-catenin pathway and immune microenvironment in lung cancer, ovarian cancer and alveolar rhabdomyosarcoma [39–41]. The gene discussed is CTNNB1; the disease is lung carcinoma.